Advances in Clinical and Experimental Medicine

Adv Clin Exp Med
Impact Factor (IF) – 1.514
Index Copernicus (ICV 2018) – 157.72
MNiSW – 40
Average rejection rate – 84.38%
ISSN 1899–5276 (print)
ISSN 2451-2680 (online)
Periodicity – monthly

Download PDF

Advances in Clinical and Experimental Medicine

2018, vol. 27, nr 9, September, p. 1201–1209

doi: 10.17219/acem/69003

Publication type: original article

Language: English

Download citation:

  • BIBTEX (JabRef, Mendeley)
  • RIS (Papers, Reference Manager, RefWorks, Zotero)

Creative Commons BY-NC-ND 3.0 Open Access

Frequency of isolation and drug susceptibility of bacterial strains isolated from child oncohematological patients 2011–2014: A single center study

Beata Kowalska-Krochmal1,A,B,C,D,E,F, Radosław Chaber2,3,A,C,D,E,F, Katarzyna Jermakow4,B,C, Magdalena Hurkacz5,C, Elżbieta Piątkowska1,B, Grażyna Gościniak4,B,C, Grażyna Wróbel2,B,C,E,F

1 Department of Pharmaceutical Microbiology and Parasitology, Wroclaw Medical University, Poland

2 Chair and Clinic of Pediatric Hematology, Oncology and Bone Marrow Transplantation, Wroclaw Medical University, Poland

3 Department of Pediatric Oncology and Hematology, Faculty of Medicine, University of Rzeszów, Poland

4 Chair and Department of Microbiology, Wroclaw Medical University, Poland

5 Chair and Department of Clinical Pharmacology, Wroclaw Medical University, Poland


Background. Infections in pediatric patients with oncohematological diseases pose a huge therapeutic and diagnostic problem.
Objectives. The aim of the study was to investigate the etiology of bacteremia and the antibiotic susceptibility of pathogenic and colonizing bacterial strains in pediatric oncohematological patients.
Material and Methods. In the period 2011–2014, 17,209 positive test results, including 1,129 positive blood cultures, were subjected to a detailed analysis. The assessment of drug susceptibility was conducted in accordance with the CLSI (American), EUCAST (European), and KORLD (Polish) recommendations.
Results. A high percentage (86–91%) of negative blood culture results was demonstrated. A predominance of Gram-positive bacteria was seen in all years (60–70%) in contrast to Gram-negative strains (30–40%). Coagulase-negative staphylococci (CNS) were the strains most frequently isolated from blood (41–47%) among all bacterial strains. Susceptibility to linezolid and vancomycin was 96–100%, and to teicoplanin 82–96%. Methicyllin-resistant coagulase-negative Staphylococcus (MRCNS) were isolated in 77–86%. All Staphylococcus aureus (S. aureus) strains were susceptible to glycopeptides and linezolid, while Enterococcus spp. was susceptible to linezolid. Apart from the year 2014, no methicillin-resistant S. aureus (MRSA) were isolated. Enterobacteriaceae (EN) were the most susceptible to imipenem and meropenem (91–100%) as well as to amikacin (77–93%). From 2013 to 2014, non-fermentative rods (NF) isolated from blood were less susceptible to imipenem and meropenem (71% and 67–71%, respectively) than to other antibiotics. It has been shown that strains isolated from blood have a statistically significantly different susceptibility to antibiotics (CNS and EN are less and NF is more susceptible) than those existing as colonizing flora.
Conclusion. Our results show that choosing appropriate antibiotics for treating infection in children with oncohematological diseases based on antibiograms for colonizing flora may be difficult because they may not take into account the more resistant strains. According to the antibiotic susceptibility of the strains isolated from blood in our center, the most viable active empirical and carbapenem-saving therapy could be conducted with piperacillin/tazobactam or cefepime.

Key words

antibiotic susceptibility, blood infections, oncohematological children

References (30)

  1. Gustinetti G, Mikulska M. Bloodstream infections in neutropenic cancer patients: A practical update. Virulence. 2016;7(3):280–297. doi: 10.1080/21505594.2016.1156821
  2. Skovbjerg S, Welinder‐Olsson C, Kondori N, et al. Optimization of the detection of microbes in blood from immunocompromised patients with haematological malignancies. Clin Microbiol Infect. 2009;15(7): 680–683.
  3. Xu J, Moore JE, Millar BC, et al. Improved laboratory diagnosis of bacterial and fungal infections in patients with hematological malignancies using PCR and ribosomal RNA sequence analysis. Leuk Lymphoma. 2004;45:1637–1641.
  4. Mancini N, Clerici D, Diotti R, et al. Molecular diagnosis of sepsis in neutropenic patients with haematological malignancies. J Med Microbiol. 2008;57:601–604.
  5. Lehrnbecher T, Phillips R, Alexander S, et al. Guideline for the management of fever and neutropenia in children with cancer and/or undergoing hematopoietic stem-cell transplantation. J Clin Oncol. 2012;30(35):4427–4438.
  6. Oliver JD. Recent findings on the viable but nonculturable state in pathogenic bacteria. FEMS Microbiol Rev. 2010;34(4):415–425. doi: 10.1111/j.1574-6976.2009.00200
  7. Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing. CLSI ; Twenty-First Informational Supplement. CLSI document M100-S21. Clinical and Laboratory Standards Institute, Wayne, PA, 2011.
  8. The European Committee on Antimicrobial Susceptibility Testing – EUCAST. Clinical breakpoints v. 1.3, v.2, v.3.1, v.4. Accessed January 6, 2014.
  9. Krajowy Ośrodek Referencyjny ds. Lekowrażliwości Drobnoustrojów – KORLD. Accessed April 10, 2013.
  10. Gaytán-Martínez J, Mateos-García E, Sánchez-Cortés E, González-Llaven J, Casanova-Cardiel LJ, Fuentes-Allen JL. Microbiological findings in febrile neutropenia. Arch Med Res. 2000;31:388–392.
  11. Asturias EJ, Corral JE, Quezada J. Evaluation of six risk factors for the development of bacteremia in children with cancer and febrile neutropenia. Curr Oncol. 2010;17(2):59–63.
  12. Greenberg D, Moser A, Yagupsky P, et al. Microbiological spectrum and susceptibility patterns of pathogens causing bacteraemia in paediatric febrile neutropenic oncology patients: comparison between two consecutive time periods with use of different antibiotic treatment protocols. Int J Antimicrob Agents. 2005;25:469–473.
  13. Duncan C, Chisholm JC, Freeman S, Riley U, Sharland M, Pritchard-Jones K. A prospective study of admissions for febrile neutropenia in secondary paediatric units in South East England. Pediatr Blood Cancer. 2007;49:678–681.
  14. Koivula I, Hämäläinen S, Jantunen E, et al. Elevated procalcitonin predicts Gram-negative sepsis in haematological patients with febrile neutropenia. Scand J Infect Dis. 2011;43(6–7):471–478. doi: 10.3109/ 00365548.2011.554855
  15. Carlet J. The gut is the epicentre of antibiotic resistance. Antimicrob Resist Infect Control. 2012;1(1):1–7.
  16. Szmyd K, Wróbel G, Węcławek-Tompol J, Wójcik D, Dobaczewski G, Chybicka A. Czynniki ryzyka wystąpienia zakażenia krwi u dzieci z upośledzoną odpornością. Adv Clin Exp Med. 2004;13(4):575–580.
  17. Mikulska M, Viscoli C, Orasch C, et al. Aetiology and resistance in bacteraemias among adult and paediatric haematology and cancer patients. J Infect. 2014;68(4):321–331.
  18. Al-Mulla NA, Taj-Aldeen SJ, El Shafie S, Janahi M, Al-Nasser AA, Chandra P. Bacterial bloodstream infections and antimicrobial susceptibility pattern in pediatric hematology/oncology patients after anticancer chemotherapy. Infect Drug Resist. 2014;7:289–299.
  19. Lv H, Ning BT, Wu XY, et al. Clinical features of bloodstream infection in children with haematological malignancies. Hong Kong J Paediatr. 2013;18(1):12–18.
  20. Kowalska-Krochmal B, Dolna I, Ruczkowska J, et al. Częstość izolacji i wrażliwość na antybiotyki bakterii od dzieci z oddziału hematologii (Wrocław, 1999–2000 vs 2001–2002). Adv Clin Exp Med. 2004;13(2): 215–226.
  21. Castagnola E, Rossi MR, Cesaro S, et al. Incidence of bacteremias and invasive mycoses in children with acute non-lymphoblastic leukemia: Results from a multi-center Italian study. Pediatr Blood Cancer. 2010;55:1103–1107.
  22. Simon A, Ammann RA, Bode U, et al. Healthcare-associated infections in pediatric cancer patients: Results of a prospective surveillance study from university hospitals in Germany and Switzerland. BMC Infect Dis. 2008;8:70–79.
  23. Nørgaard M. Risk of infections in adult patients with haematological malignancies. Open Infect Dis J. 2012;6(1):46–51.
  24. Gedik H, Şimşek F, Yıldırmak T, et al. Which multidrug resitant bacteria are emerging in patients with hematological malignancies?: One-Year Report. Indian J Hematol Blood Transfus. 2015;31(1):51–56.
  25. Villafuerte-Gutierrez P, Villalon L, Losa JE, Henriquez-Camacho C. Treatment of febrile neutropenia and prophylaxis in hematologic malignancies: A critical review and update. Adv Hematol. 2014.
  26. Freifeld AG, Bow EJ, Sepkowitz KA, et al. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 Update by the Infectious Diseases Society of America. Clin Infect Dis. 2011;52:427–431.
  27. Bucaneve G, Micozzi A, Menichetti F, et al. Levofloxacin to prevent bacterial infection in patients with cancer and neutropenia. N Engl J Med. 2005;353:977–987.
  28. Kern WV, Klose K, Jellen-Ritter AS, et al. Fluoroquinolone resistance of Escherichia coli at a cancer center: Epidemiologic evolution effects of discontinuing prophylactic fluoroquinolone use in neutropenic patients with leukemia. Eur J Clin Microbiol Infect Dis. 2005;24:111–118.
  29. Aslan S, Citak EC, Yis R, Degirmenci S, Arman D. Bacterial spectrum and antimicrobial susceptibility pattern of bloodstream infections in children with febrile neutropenia: Experience of single center in southeast of Turkey. Indian J Microbiol. 2012;52(2):203–208.
  30. Trecarichi EM, Tumbarello M. Antimicrobial-resistant Gram-negative bacteria in febrile neutropenic patients with cancer: Current epidemiology and clinical impact. Curr Opin Infect Dis. 2014;27(2):200–210.